<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346655</url>
  </required_header>
  <id_info>
    <org_study_id>2017/1358</org_study_id>
    <nct_id>NCT03346655</nct_id>
  </id_info>
  <brief_title>Brain Metastases in Norway - A Prospective Cohort Study</brief_title>
  <official_title>Brain Metastases in Norway - Improved Classification and Treatment. A Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South-Eastern Norway Regional Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim and primary outcome of this study will be a descriptive analysis of the&#xD;
      current treatment practice of BM in Norway. Specifically, it may give answers to the&#xD;
      following research questions:&#xD;
&#xD;
        -  What is the true incidence of BM in Norway?&#xD;
&#xD;
        -  How are patients with BM treated at present?&#xD;
&#xD;
        -  Do treatments differ between hospitals?&#xD;
&#xD;
        -  How do treatments impact quality of life of the patients?&#xD;
&#xD;
        -  Which factors (treatment, tumor and host variables) can explain disease control,&#xD;
           survival, symptom relief, and general functions?&#xD;
&#xD;
        -  How can BM staging be improved?&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Overall survival after diagnosis of brain metastases</measure>
    <time_frame>Time from diagnosis of brain metastases till death of any cause, assessed up to 12 months</time_frame>
    <description>Calculation of the overall survival times for each patient enrolled</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment offered to patients diagnosed with brain metastases</measure>
    <time_frame>3 years</time_frame>
    <description>Description of treatment offered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in patient reported symptoms and quality of life items through EORTC questionnaire QLQ PAL15 and submodule BN20</measure>
    <time_frame>Monthly up to 12 months after inclusion</time_frame>
    <description>Description of changes in patient reported outcomes through standardized questionnaires.European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients receiving palliative care (EORTC QLQ-C15-PAL), covers items such as pain, physical and emotional functioning. The QLQ-BN20 contains questions on 7 single-item symptom scales (headaches, seizures, drowsiness, hair loss, itchy skin, leg weakness, and bladder control), and 4 multi-item scales (future uncertainty, visual disorder, motor dysfunction, and communication deficit). Patient's scores are translated into a scale from 1-100. A change of 10 points in one item is considered clinically significant.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Brain Metastases</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients With previously or newly diagnosed cancer With radiologically proven brain&#xD;
        metastases&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Verified cancer diagnosis of solid tumors (based on radiological,&#xD;
             histological/cytological or operative evidence).&#xD;
&#xD;
          -  Brain metastases verified by computer tomography (CT), contrast-enhanced magnetic&#xD;
             resonance imaging (MRI), or surgical biopsies&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Able to comply with study procedures&#xD;
&#xD;
          -  Able to provide written informed consent after information in Norwegian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary brain tumors&#xD;
&#xD;
          -  Primary hematological malignancies (lymphomas, leukemias)&#xD;
&#xD;
          -  Previous diagnosis and/or treatment of BM&#xD;
&#xD;
          -  Unable to produce written informed consent after information in Norwegian&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olav E Yri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Post-doc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stein Kaasa, Professor</last_name>
    <phone>+47 22 93 40 00</phone>
    <email>stekaa@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marianne Jensen Hjermstad, Professor</last_name>
    <phone>+47 23 02 68 28</phone>
    <email>marianne.j.hjermstad@ntnu.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olav E Yri, MD, PhD</last_name>
      <phone>+47 22 93 40 00</phone>
      <email>olavy@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Marianne Jensen Hjermstad, Professor</last_name>
      <phone>+47 23 02 68 28</phone>
      <email>marianne.j.hjermstad@ntnu.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 7, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Olav Erich Yri</investigator_full_name>
    <investigator_title>MD, PhD, Postdoctoral research fellow</investigator_title>
  </responsible_party>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

